Tumor heterogeneity in the clinic: Is it a real problem?

Therapeutic Advances in Medical Oncology

Volumn 6, Issue 2, 2014, Pages 43-51

  Janku, Filip ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

molecular aberrations; targeted therapies; tumor heterogeneity

Indexed keywords

IMATINIB;

ADVANCED CANCER; CANCER CELL; CANCER CELL POPULATION HETEROGENEITY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; GENETIC HETEROGENEITY; GOLD STANDARD; HEALTH CENTER; HUMAN; METASTASIS; MOLECULAR DIAGNOSTICS; MOLECULARLY TARGETED THERAPY; NEOPLASM; PERSONALIZED MEDICINE; PLASMA; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR GROWTH;

EID: 84899129255     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834013517414     Document Type: Review

References (59)

1. Amado R. Wolf M. Peeters M. van Cutsem E. Siena S. Freeman D. et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626–1634.
2. Braun S. Pantel K. Muller P. Janni W. Hepp F. Kentenich C. et al. (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342: 525–533.
3. Carracedo A. Ma L. Teruya-Feldstein J. Rojo F. Salmena L. Alimonti A. et al. (2008) Inhibition of MTORC 1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065–3074.
4. Chakrabarty A. Rexer B. Wang S. Cook R. Engelman J. Arteaga C. (2010) H1047r Phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 29: 5193–5203.
5. Cho K. Vogelstein B. (1992) Genetic alterations in the adenoma–carcinoma sequence. Cancer 70: 1727–1731.
6. Correia A. Bissell M. (2012) The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updates 15: 39–49.
7. Crowley E. Di Nicolantonio F. Loupakis F. Bardelli A. (2013) Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10: 472–484.
8. Dawson S. Tsui D. Murtaza M. Biggs H. Rueda O. Chin S. et al. (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368: 1199–1209.
9. de Mattos-Arruda L. Cortes J. Santarpia L. Vivancos A. Tabernero J. Reis-Filho J. et al. (2013 a) Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 10: 377–389.
10. de Mattos-Arruda L. Oliveira M. Navarro A. Vilaro M. Nuciforo P. Vivancos A. et al. (2013 b) Molecular profiling of advanced breast cancer patients and benefit obtained from matched targeted therapy in early phase clinical trials. In Proceedings European Cancer Congress 2013, Amsterdam.
11. Diaz L. Jr. Williams R. Wu J. Kinde I. Hecht J. Berlin J. et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537–540.
12. Diehl F. Schmidt K. Choti M. Romans K. Goodman S. Li M. et al. (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985–990.
13. Dienstmann R. Serpico D. Rodon J. Saura C. Macarulla T. Elez E. et al. (2012) Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase 1 clinical trials. Mol Cancer Ther 11: 2062.
14. Druker B. Talpaz M. Resta D. Peng B. Buchdunger E. Ford J. et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037.
15. Dupont Jensen J. Laenkholm A. Knoop A. Ewertz M. Bandaru R. Liu W. et al. (2011) PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17: 667–677.
16. El-Osta H. Hong D. Wheler J. Fu S. Naing A. Falchook G. et al. (2011) Outcomes of research biopsies in phase I clinical trials: the MD Anderson Cancer Center experience. Oncologist 16: 1292–1298.
17. Engelman J. Chen L. Tan X. Crosby K. Guimaraes A. Upadhyay R. et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant KRAS G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351–1356.
18. Engelman J. Zejnullahu K. Mitsudomi T. Song Y. Hyland C. Park J. et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB 3 signaling. Science 316: 1039–1043.
19. Faber A. Corcoran R. Ebi H. Sequist L. Waltman B. Chung E. et al. (2011) BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 1: 352–365.
20. Falchook G. Lewis K. Infante J. Gordon M. Vogelzang N. Demarini D. et al. (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. The lancet oncology 13: 782–789.
21. Falchook G. Long G. Kurzrock R. Kim K. Arkenau T. Brown M. et al. (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379: 1893–1901.
22. Flaherty K. Puzanov I. Kim K. Ribas A. Mcarthur G. Sosman J. et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809–819.
23. Forshew T. Murtaza M. Parkinson C. Gale D. Tsui D. Kaper F. et al. (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4: 136ra168.
24. Gerlinger M. Rowan A. Horswell S. Larkin J. Endesfelder D. Gronroos E. et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883–892.
25. Gilbert L. Hemann M. (2010) DNA damage-mediated induction of a chemoresistant niche. Cell 143: 355–366.
26. Gonzalez-Angulo A. Ferrer-Lozano J. Stemke-Hale K. Sahin A. Liu S. Barrera J. et al. (2011) PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10: 1093–1101.
27. Hatzivassiliou G. Song K. Yen I. Brandhuber B. Anderson D. Alvarado R. et al. (2010) RAF inhibitors prime wild-type RAF to activate the mapk pathway and enhance growth. Nature 464: 431–435.
28. Holzel M. Bovier A. Tuting T. (2013) Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 13: 365–376.
29. Janku F. Kleibl Z. Novotny J. Tesarova P. Petruzelka L. Matous B. (2004) Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer. Neoplasma 51: 204–208.
30. Janku F. Lee J. Tsimberidou A. Hong D. Naing A. Falchook G. et al. (2011) PIK3CA Mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PloS ONE 6: e22769.
31. Janku F. Srovnal J. Korinkova G. Novotny J. Petruzelka L. Power D. et al. (2008) Molecular detection of disseminated breast cancer cells in the bone marrow of early breast cancer patients using quantitative RT PCR for CEA. Neoplasma 55: 317–322.
32. Kaelin W. Jr. (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5: 689–698.
33. Kim E. Herbst R. Wistuba I. Lee J. Blumenschein G. Jr. Tsao A. et al. (2011) The battle trial: personalizing therapy for lung cancer. Cancer Discov 1: 44–53.
34. Kopetz S. Desai J. Chan E. Hecht J. O'dwyer J. Lee R. et al. (2010) PLX 4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28: abstract 3534.
35. Leary R. Kinde I. Diehl F. Schmidt K. Clouser C. Duncan C. et al. (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2: 20ra14.
36. Lengauer C. Kinzler K. Vogelstein B. (1998) Genetic instabilities in human cancers. Nature 396: 643–649.
37. Leon S. Shapiro B. Sklaroff D. Yaros M. (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37: 646–650.
38. Lynch T. Bell D. Sordella R. Gurubhagavatula S. Okimoto R. Brannigan B. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.
39. Mao M. Tian F. Mariadason J. Tsao C. Lemos R. Jr. Dayyani F. et al. (2013) Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 19: 657–667.
40. Meric-Bernstam F. Mills G. (2012) Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 9: 542–548.
41. Misale S. Yaeger R. Hobor S. Scala E. Janakiraman M. Liska D. et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532–536.
42. Murtaza M. Dawson S. Tsui D. Gale D. Forshew T. Piskorz A. et al. (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497: 108–112.
43. Nawroz H. Koch W. Anker P. Stroun M. Sidransky D. (1996) Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 2: 1035–1037.
44. Nazarian R. Shi H. Wang Q. Kong X. Koya R. Lee H. et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973–977.
45. O'Dwyer M. Mauro M. Kurilik G. Mori M. Balleisen S. Olson S. et al. (2002) The Impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100: 1628–1633.
46. Prahallad A. Sun C. Huang S. Di Nicolantonio F. Salazar R. Zecchin D. et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100–103.
47. Rodrik-Outmezguine V. Chandarlapaty S. Pagano N. Poulikakos P. Scaltriti M. Moskatel E. et al. (2011) MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1: 248–259.
48. Sequist L. Martins R. Spigel D. Grunberg S. Spira A. Janne P. et al. (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26: 2442–2449.
49. Sequist L. Waltman B. Dias-Santagata D. Digumarthy S. Turke A. Fidias P. et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26.
50. Shapiro B. Chakrabarty M. Cohn E. Leon S. (1983) Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51: 2116–2120.
51. Slamon D. Leyland-Jones B. Shak S. Fuchs H. Paton V. Bajamonde A. et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792.
52. Tsimberidou A. Iskander N. Hong D. Wheler J. Falchook G. Fu S. et al. (2012) Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 18: 6373–6383.
53. Turner N. Reis-Filho J. (2012) Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13: e178–e185
54. van Cutsem E. Kohne C. Hitre E. Zaluski J. Chang Chien C. Makhson A. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408–1417.
55. Wagle N. Berger M. Davis M. Blumenstiel B. Defelice M. Pochanard P. et al. (2012) High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2: 82–93.
56. Wagle N. Emery C. Berger M. Davis M. Sawyer A. Pochanard P. et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29: 3085–3096.
57. Weinstein I. (2002) Cancer. Addiction to oncogenes–the achilles heal of cancer. Science 297: 63–64.
58. Westin J. Kurzrock R. (2012) It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther 11: 2549–2555.
59. Wood L. Parsons D. Jones S. Lin J. Sjoblom T. Leary R. et al. (2007) The Genomic landscapes of human breast and colorectal cancers. Science 318: 1108–1113.